Molecular Target: Human Epidermal Growth Factor Receptor 2 (HER2)

Review important resource on HER2. Given recent approvals, the SGO Education Committee strongly encourages HER2 to be completed on patients with high risk for recurrence or with confirmed recurrence to evaluate for possible use of HER2 targeted therapies. 

Created by the Chemotherapy and Immunotherapy Subcommittee of the SGO Education Committee. 

Target Audience

Physicians, Fellows, Residents, SGO Members

You may also be interested in

Keeping up with the Chemos Series on Trastuzumab Deruxtecan ENHERTU®: Preparing to Give It (Pt. 1)
​​​​​This is the first of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®. Tune in as the multidisciplinary panel reviews general information (such as when to use, checking patient performance status, tox
Keeping up with the Chemos Series on Trastuzumab Deruxtecan ENHERTU®: Administration (Pt. 2)
​​​​This is the second of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®. Tune in as the multidisciplinary panel discusses administration, focusing on dosing, breast scoring, HER2, infusion reactions, lab examinations, and patient e
Keeping up with the Chemos Series on Trastuzumab Deruxtecan ENHERTU®: Monitoring Between Cycles (Pt. 3)
This is the third episode in the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®. Tune in as the panel explores challenges with patient monitoring, when to dose adjust and hold, or even discontinue, before concluding with a few take home
Course summary
Course opens: 
06/27/2024
Course expires: 
06/27/2028
Cost:
$0.00

Price

Cost:
$0.00
Please login or register to take this course.